Pfizer Inc. (NYSE:PFE) Shares Acquired by Conning Inc.

Conning Inc. raised its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 13.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,208,125 shares of the biopharmaceutical company's stock after acquiring an additional 142,872 shares during the period. Pfizer accounts for approximately 1.2% of Conning Inc.'s portfolio, making the stock its 26th largest position. Conning Inc.'s holdings in Pfizer were worth $34,715,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of PFE. Moneta Group Investment Advisors LLC boosted its stake in shares of Pfizer by 89,592.7% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company's stock worth $8,257,000,000 after buying an additional 160,963,976 shares during the period. Norges Bank acquired a new stake in shares of Pfizer during the fourth quarter worth about $3,150,472,000. Charles Schwab Investment Management Inc. boosted its stake in shares of Pfizer by 10.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company's stock worth $3,161,261,000 after buying an additional 9,393,992 shares during the period. Morgan Stanley boosted its stake in shares of Pfizer by 10.3% during the fourth quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company's stock worth $4,073,547,000 after buying an additional 7,419,929 shares during the period. Finally, Renaissance Technologies LLC acquired a new stake in shares of Pfizer during the first quarter worth about $311,238,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Price Performance

Shares of PFE traded down $0.48 during mid-day trading on Friday, reaching $25.86. 43,034,056 shares of the company's stock were exchanged, compared to its average volume of 35,130,948. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The company has a 50-day simple moving average of $27.28 and a two-hundred day simple moving average of $28.88. Pfizer Inc. has a 52-week low of $25.61 and a 52-week high of $41.71. The company has a market cap of $146.43 billion, a price-to-earnings ratio of 71.83, a PEG ratio of 1.16 and a beta of 0.61.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion during the quarter, compared to analysts' expectations of $14.37 billion. During the same period last year, the company posted $1.14 EPS. The company's revenue was down 41.3% on a year-over-year basis. On average, sell-side analysts predict that Pfizer Inc. will post 2.22 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Guggenheim initiated coverage on shares of Pfizer in a research note on Friday, February 23rd. They set a "buy" rating and a $36.00 target price for the company. Argus downgraded shares of Pfizer from a "buy" rating to a "hold" rating in a research report on Friday, March 22nd. TD Cowen downgraded shares of Pfizer from an "outperform" rating to a "market perform" rating and set a $32.00 price objective for the company. in a research report on Thursday, January 4th. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday, April 1st. Twelve investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, Pfizer presently has a consensus rating of "Hold" and a consensus price target of $36.88.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.